News
-
Gossamer Bio, which is developing inhaled dry powder seralutinib, announced a deal with Samsara BioCapital giving the company an option to acquire Respira Therapeutics along with Respira’s RT234 vardenafil DPI. On signing, Gossamer will issue 2.5 million… Read more . . .
-
Inhaler testing specialist Copley Scientific has announced the appointment of Paul Martin as Head of Business Development. Martin, who has extensive experience in business development within the OINDP space, was most recently Associate Director of… Read more . . .
-
Blow Fill Seal specialist Ritedose, which offers CDMO services and produces its own inhalation solutions, has announced that it will spend $17 million to add 10,000 sq ft of laboratory space, tripling its current lab… Read more . . .
-
Acadia Pharmaceuticals has announced that the Phase 3 COMPASS PWS trial of ACP-101 carbetocin nasal spray in Prader-Willi syndrome patients with hyperphagia failed to meet any of its endpoints, including the primary endpoint of change… Read more . . .
-
Nano PharmaSolutions and CDMO Mikart have announced limited data from an ongoing Phase 1 trial of Nano PharmaSolutions’ NT-301 apomorphine nasal powder, which is in development for the treatment of OFF episodes in Parkinson’s disease.… Read more . . .
-
Polyrizon announced that it has submitted a pre-submission package to the FDA for its PL-14 Allergy Blocker nasal spray. The company describes the product as “a novel, non-invasive nasal spray that forms a physical barrier… Read more . . .
-
According to ARS Pharmaceuticals, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved 1mg and 2mg doses of neffy epinephrine nasal spray for the treatment of anaphylaxis in people who weigh more than 15 kilograms.… Read more . . .
-
AstraZeneca announced that the FDA has approved the company’s supplemental NDA to add data related to the treatment of mild asthma to the label for Airsupra albuterol / budesonide MDI. In October 2024, AstraZeneca and… Read more . . .
-
Neumifil antiviral nasal spray developer Pneumagen has announced the launch of a platform called NeumoBind for intranasal protein formulations. The company says, “By anchoring proteins in place on a mucosal surface, NeumoBind addresses a critical… Read more . . .
-
According to Corstasis Therapeutics, the FDA has approved the company’s NDA for Enbumyst (RSQ-777) bumetanide nasal spray for the treatment of edema associated with heart, kidney, and liver disease. In January 2025, Corstasis announced that… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK